about
Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral OncologyIndividual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European group for blood and marrow transplantation.Novel therapeutic options in Acute Myeloid LeukemiaNovel Prognostic and Therapeutic Mutations in Acute Myeloid LeukemiaA gain-of-function mutation of JAK2 in myeloproliferative disordersHematopoietic SCT in Europe: data and trends in 2011.Persistence of recipient-type endothelium after allogeneic hematopoietic stem cell transplantation.Haematopoetic stem cell transplantation for refractory autoimmune cytopenia.Haematopoietic stem cell transplantation for immune thrombopenia and other refractory autoimmune cytopenias.Transplant-associated microangiopathy (TAM) in recipients of allogeneic hematopoietic stem cell transplants.Cyclosporine-responsive thrombocytopenia in a patient with chloramphenicol-associated myelodysplastic syndrome.Hematopoetic stem cell transplantation for immune thrombocytopenia and other refractory autoimmune cytopenias.Do NK cells contribute to the pathophysiology of transplant-associated thrombotic microangiopathy?Third-party mesenchymal stromal cell infusion is associated with a decrease in thrombotic microangiopathy symptoms observed post-hematopoietic stem cell transplantation.Azacytidine for acute myeloid leukemia in elderly or frail patients: a phase II trial (SAKK 30/07).Heterogeneity in clinical course of EBV-associated lymphoproliferative disorder after allogeneic stem cell transplantation.Influence of selective serotonin reuptake inhibitors on bleeding risk in patients with severe thrombocytopenia after chemotherapy: a retrospective study.Management of hemolytic anemia following allogeneic stem cell transplantation.Human platelet antigen antibody induction in uncomplicated pregnancy is associated with HLA sensitization.Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera.[Establishing an umbilical cord blood bank for unrelated allogenic stem cell transplantation]Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantationHematopoietic stem cell transplantation for autoimmune disorders.Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report.Autologous haematopoietic stem cell transplants for autoimmune disease--feasibility and transplant-related mortality. Autoimmune Disease and Lymphoma Working Parties of the European Group for Blood and Marrow Transplantation, the European League AgaImmunological and autoimmune considerations of Autism Spectrum Disorders.Weekly use of fluconazole as prophylaxis in haematological patients at risk for invasive candidiasisAutologous bone marrow mononuclear cell transplantation in patients with decompensated alcoholic liver disease: a randomized controlled trial.IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA.The survey on cellular and engineered tissue therapies in Europe in 2012.Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastiHematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants.Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysisConditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT.A rare case of coinheritance of Hemoglobin H disease and sickle cell trait combined with severe iron deficiencyInfluence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the Infectious Diseases and Acute Leukemia Working Parties.Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimensHaematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow TransplantationEarly administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMTHLA-matched sibling transplantation for severe aplastic anemia: impact of HLA DR15 antigen status on engraftment, graft-versus-host disease, and overall survival.
P50
Q27026718-85E1C85D-AF9F-4426-B5C9-FE56C462E5A8Q27690791-10938617-EEB9-446C-9F47-3A29C1F3164AQ28069889-9A3CF920-6931-40BB-8F38-EA72D0ED6F68Q28075654-47B58B63-C123-4E1A-A2F0-BA9B45FF6CEAQ29618851-4660924E-D952-4253-AB6E-33E0E39CFBACQ30616418-44532C7E-6365-4EF7-812E-1F1FEE414A2AQ30990142-7744C81B-87FA-4EB6-B3DD-ADAD1C67AFEBQ33361139-93E19875-9578-4C2F-B2BF-9B08E1E031A0Q33362076-DE6FE928-C3A3-48DB-A4AD-423133262041Q33368614-F256AB09-0AF3-4770-9947-7C37B86493B5Q33370159-C7C8D506-3584-433E-9451-584C57615B94Q33381818-F30D30CF-D8A5-4378-8F1A-9E505DB8B634Q33395998-6A3A2620-8876-4D53-A4B3-400B5FFC63FEQ33398627-074750CF-7C09-4ED7-B2C0-62716B5CB0B3Q33406770-5A21B076-9D63-4CC9-8901-F8E8417CD854Q33410603-DB1A2976-6EAB-49C1-99ED-FC619A006E0FQ33419146-68CB8D2E-B6EE-4BA6-9F97-EBAA7D38F9FBQ33428168-0FC20194-A51C-4291-9A9D-7EE4782A92A1Q33440153-BA119D11-26EA-43CC-998B-67DDD3E8042DQ33443580-279A0AAE-BB33-4271-BA99-698C4D96E08DQ33464693-39A20A3F-5D09-4F91-A48C-4009AC581B74Q33733022-A271F893-4D4B-418B-B966-B632A8F53DABQ33765235-160ECC00-592D-434F-9854-92804D3B994BQ33786536-C6B58868-0D9C-48B7-9447-CDFC8E3E73FEQ33876528-D68576C0-D692-4364-91F6-E4EEA1A73E3FQ34037512-C002E68E-24BD-48CC-AD2C-B7FCCF4EAC05Q34517297-96D530F4-7AC6-4BE3-AAF7-001B0B7C1EC1Q34558638-E5751C43-6D6F-4114-A48C-0C05B72ED47FQ34625042-D708BF28-AF98-40E0-A71F-ED0668C8A36FQ34938449-82EBA0AF-5526-4D5C-A910-B33693E22145Q35146316-F6CCA6D1-46B1-4E8E-9D74-969205CE88D0Q35288778-3A65269B-2B08-468E-A997-321C2EAC9DA7Q35571068-0658486E-7971-4539-A458-17A6391918ECQ35647641-D78ABEC8-AD76-4050-90B5-27DA5288CEBAQ35720070-B74A2759-2142-414E-9E3D-DFF80F715EEEQ35821259-90701439-6C4A-442C-AA0C-DBFAD0988034Q35828656-EABD92E7-0DA4-4F82-A96B-FE1AFF700EDCQ36020897-6CF3B461-5673-4B53-B9CC-C4374E9B6463Q36036334-F97E557F-6F25-44A3-8AC5-8FC9E1EE770EQ36120565-BAE2BB02-ACD7-430C-B2C4-D55DC4384DA6
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
wetenschapper
@nl
研究者
@zh
name
J Passweg
@ast
J Passweg
@nl
Jakob R. Passweg
@en
Jakob R. Passweg
@es
type
label
J Passweg
@ast
J Passweg
@nl
Jakob R. Passweg
@en
Jakob R. Passweg
@es
altLabel
J Passweg
@en
J R Passweg
@en
J. Passweg
@en
J. R. Passweg
@en
Jakob Passweg
@en
Jakob R Passweg
@en
Passweg J
@en
Passweg J. R.
@en
Passweg J.
@en
Passweg JR
@en
prefLabel
J Passweg
@ast
J Passweg
@nl
Jakob R. Passweg
@en
Jakob R. Passweg
@es
P31
P496
0000-0001-7092-3351